{"id":390667,"date":"2018-05-25T00:00:00","date_gmt":"2018-05-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0021-2018-biopharma-chronic-low-back-pain-unmet-need-us-eu-2018\/"},"modified":"2026-04-17T05:29:01","modified_gmt":"2026-04-17T05:29:01","slug":"unnecg0021-2018-biopharma-chronic-low-back-pain-unmet-need-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0021-2018-biopharma-chronic-low-back-pain-unmet-need-us-eu-2018\/","title":{"rendered":"Chronic Low Back Pain | Unmet Need | US\/EU | 2018"},"content":{"rendered":"<p>Chronic low back pain (<abbr title=\"chronic low back pain\">CLBP<\/abbr>), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain therapy market and thus is an attractive commercial opportunity for drug developers. Although rates of prescription drug treatment are high, a sizable proportion of patients are untreated or have pain that is inadequately controlled with current therapies, primarily nonsteroidal anti-inflammatory drugs (<abbr title=\"nonsteroidal anti-inflammatory drug\">NSAID<\/abbr>s), opioid analgesics (including opioid-acetaminophen combinations), dual-acting opioid analgesics, and antiepileptic drugs. This content provides quantitative insight into U.S. and European physicians\u2019 perceptions of key treatment drivers and goals in the management of <abbr title=\"chronic low back pain\">CLBP<\/abbr>, the current level of unmet need in this indication, and an analysis of the commercial opportunities in this area.<\/p>\n<p><strong>Questions\u00a0Answered<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for <abbr title=\"chronic low back pain\">CLBP<\/abbr>?<\/li>\n<li>What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies such as acetaminophen-hydrocodone (AbbVie\u2019s Vicodin, generics) and pregabalin (Pfizer\u2019s Lyrica, generics) perform on key treatment drivers and goals for <abbr title=\"chronic low back pain\">CLBP<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <abbr title=\"chronic low back pain\">CLBP<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. <abbr title=\"primary care physician\">PCP<\/abbr>s and European <abbr title=\"general practitioner\">GP<\/abbr>s for a hypothetical new analgesic for <abbr title=\"chronic low back pain\">CLBP<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Product\u00a0Description<\/strong><\/p>\n<p><em>Unmet Need:<\/em> Provides quantitative insight into U.S. and European physicians\u2019 perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, and Germany.<\/p>\n<p><strong>Primary research: <\/strong> Survey of 60 <abbr title=\"primary care physician\">PCP<\/abbr>s in the United States and 30 <abbr title=\"general practitioner\">GP<\/abbr>s in Europe.<\/p>\n<p><strong>Key companies:\u00a0<\/strong>AbbVie, Endo Pharmaceuticals, Iroko Pharmaceuticals, Mundipharma International,\u00a0Napp Pharmaceuticals, Novartis,\u00a0Pfizer, and Purdue Pharma.<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Butrans, celecoxib (Celebrex, generics), diclofenac (oral; Voltaren, generics), OxyContin, pregabalin (Lyrica, generics), and acetaminophen-hydrocodone (Vicodin, generics).<\/p>\n<p><strong>Key metrics included:<\/strong><\/p>\n<ul>\n<li>Stated versus derived analysis of U.S. and European physician prescribing behavior.<\/li>\n<li>Conjoint analysis with U.S. and European physicians, includes market simulator.<\/li>\n<li>Assessment of current drug performance against treatment drivers and goals.<\/li>\n<li>Physician perceptions of unmet need in the disease covered, and related diseases.<\/li>\n<li>Analysis of remaining drug development opportunities.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390667","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390667\/revisions"}],"predecessor-version":[{"id":393791,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390667\/revisions\/393791"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}